23.07.2019 • News

Yellow Wood to Buy Dr. Scholl’s from Bayer

Yellow Wood to Buy Dr. Scholl’s from Bayer (c) Dr. Scholl’s
Yellow Wood to Buy Dr. Scholl’s from Bayer (c) Dr. Scholl’s

US private equity group Yellow Wood Partners has agreed to acquire the Dr. Scholl’s footcare business from Bayer for $585 million. Following completion of the transaction in this year’s fourth quarter, the investor plans to create a standalone company to operate it.

Yellow Wood said the footcare brand, which had 2018 sales of $234 million, “fits extremely well” with its consumer-focused business model, and it plans to take money in hand to expand it.

The 110-year-old brand the German group picked up in the 2014 acquisition of US Merck’s consumer health portfolio, is focused on North America. Reckitt Benckiser owns the Scholl footcare business outside that region.

Bayer is selling several businesses to concentrate on its ethical and over-the-counter drugs businesses and to pay down debt taken on for the Monsanto acquisition. The German group may also need cash to settle some of the more than 13,000 lawsuits it faces over Monsanto’s Roundup herbicide.

The Boston-based investor will take over Bayer’s 30 dedicated employees in the US and Canada, including staff in sales and marketing, research & development.

“Since Bayer took ownership of Dr. Scholl’s in late 2014, we have made progress in revitalizing the brand and developing an exciting pipeline of innovative products,” said Heiko Schipper, a member of the Bayer managing board and head of consumer health care.

In May, Bayer sold sun care products manufacturer Coppertone – another former Merck brand – to German cosmetics group Beiersdorf for $550m. It has not yet concluded the planned sale of its animal health business. 

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read